Objectives:To investigate the clinical value of cardiac magnetic resonance imaging(CMR)feature-tracking strain analysis in risk stratification of diabetic heart failure with preserved ejection fraction(HFpEF).Methods:In this retrospective study,a total of 215 patients with diabetic HFpEF who underwent CMR at Chinese Academy of Medical Sciences Fuwai Hospital from January 2012 to December 2018 were included.Myocardial strain parameters were calculated using CMR feature-tracking technology.Patients were followed up by medical records or telephone calls.Composite endpoint event,all-cause death or heart failure hospitalization during follow-up were recorded.Patients were divided into event group and event-free group.Univariable and multivariable Cox proportional hazard regression analyses were performed to determine the risk factors for the outcomes in diabetic HFpEF.The effects of hypertension and obesity on the prognosis of diabetic HFpEF patients and whether they affect the prognostic value of CMR feature-tracking strain analysis were also analyzed.Results:During a follow-up of(7.1±1.8)years,93(43.3%)patients had endpoint events(event group),including 28 all-cause deaths and 65 heart failure hospitalization.Compared with the event-free group(n=122),patients in the event group had significantly lower left ventricular ejection fraction,higher prevalence and extent of late gadolinium enhancement,and significantly reduced global longitudinal strain(GLS),global circumferential strain,global radial strain,and global systolic longitudinal strain rate(all P<0.05).The absolute GLS value was significantly lower in event group than in event-free group,regardless of the presence of hypertension and obesity.Multivariate Cox regression analysis showed that estimated glomerular filtration rate(HR=0.983,95%CI:0.972-0.993,P=0.001),left atrial volume index(HR=1.015,95%CI:1.005-1.026,P=0.004),and GLS(HR=1.142,95%CI:1.060-1.231,P<0.001)were independent risk factors for adverse cardiovascular events in diabetic HFpEF patients.However,adjusted N-terminal pro-brain natriuretic peptide was not an independent prognostic factor.The cut-offvalue of GLS to predict outcome was-14.09%from ROC curve analysis.The Kaplan-Meier curve showed that in patients with and without hypertension and obesity,patients with the GLS>-14.09%had lower event-free survival compared to patients with GLS≤-14.09%(all P<0.05),and the ability of GLS to predict adverse outcomes was not affected by hypertension and obesity.Conclusions:GLS obtained by CMR feature-tracking strain analysis is an independent predictor of adverse outcomes in diabetic HFpEF,and its ability to predict adverse outcomes is independent of hypertension and obesity.

Objective:To investigate the changes and significance of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and procalcitonin, C-reactive protein, and interleukin-6 levels in neonates with septicemia.Methods:This study used a retrospective analysis mehod. A total of 69 neonates with septicemia who received treatment at the Neonatal Ward, Children's Hospital, The First People's Hospital of Chu Zhou were included in the study group. A total of 43 neonates without septicemia were included in the control group. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6 (IL-6) levels were compared between the two groups. The changes in NLR, MLR, PCT, and CRP levels in neonates with septicemia were observed after treatment, compared with their pre-treatment levels. The receiver operating characteristic curve was used to analyze the value of laboratory indicators NLR, MLR, and PCT, CRP, and IL-6 levels in the diagnosis of septicemia in neonates.Results:The NLR, MLR, and PCT, CRP, and IL-6 levels in the study group were (4.79 ± 1.87), (0.49 ± 0.21), (8.41 ± 3.21) μg/L, (11.97 ± 4.23) mg/L, and (892.13 ± 361.43) ng/L, respectively. These values were significantly higher than those in the control group [(0.89 ± 0.23), (0.13 ± 0.06), (0.51 ± 0.26) μg/L, (2.16 ± 1.26) mg/L, (111.28 ± 51.69) ng/L, t = 10.11, 9.76, 23.06, 36.72, 15.74, all P < 0.05]. After treatment, NLR, MLR, and PCT and CRP levels in the study group were (3.04 ± 1.42), (0.29 ± 0.13), (1.26 ± 0.52) μg/L, and (3.28 ± 1.87) mg/L, respectively. These values were significantly lower than those measured before treatment in the same group [(4.79 ± 2.47), (0.49 ± 0.19), (8.41 ± 3.41) μg/L, (11.97 ± 5.26) mg/L, t = 6.50, 6.33, 33.05, 39.04, all P < 0.05]. The areas under the curve for NLR, MLR, and PCT, CRP, and IL-6 levels in diagnosing septicemia in neonates were 0.785, 0.765, 0.665, 0.763, and 0.753, respectively, with NLR showing the highest area under the curve. Conclusions:NLR and MLR are valuable for diagnosing and evaluating the prognosis of neonatal septicemia. Combined detection of PCT, CRP, and IL-6 levels can enhance the sensitivity and specificity of septicemia diagnosis.

Objectives:To investigate the clinical value of cardiac magnetic resonance imaging(CMR)feature-tracking strain analysis in risk stratification of diabetic heart failure with preserved ejection fraction(HFpEF).Methods:In this retrospective study,a total of 215 patients with diabetic HFpEF who underwent CMR at Chinese Academy of Medical Sciences Fuwai Hospital from January 2012 to December 2018 were included.Myocardial strain parameters were calculated using CMR feature-tracking technology.Patients were followed up by medical records or telephone calls.Composite endpoint event,all-cause death or heart failure hospitalization during follow-up were recorded.Patients were divided into event group and event-free group.Univariable and multivariable Cox proportional hazard regression analyses were performed to determine the risk factors for the outcomes in diabetic HFpEF.The effects of hypertension and obesity on the prognosis of diabetic HFpEF patients and whether they affect the prognostic value of CMR feature-tracking strain analysis were also analyzed.Results:During a follow-up of(7.1±1.8)years,93(43.3%)patients had endpoint events(event group),including 28 all-cause deaths and 65 heart failure hospitalization.Compared with the event-free group(n=122),patients in the event group had significantly lower left ventricular ejection fraction,higher prevalence and extent of late gadolinium enhancement,and significantly reduced global longitudinal strain(GLS),global circumferential strain,global radial strain,and global systolic longitudinal strain rate(all P<0.05).The absolute GLS value was significantly lower in event group than in event-free group,regardless of the presence of hypertension and obesity.Multivariate Cox regression analysis showed that estimated glomerular filtration rate(HR=0.983,95%CI:0.972-0.993,P=0.001),left atrial volume index(HR=1.015,95%CI:1.005-1.026,P=0.004),and GLS(HR=1.142,95%CI:1.060-1.231,P<0.001)were independent risk factors for adverse cardiovascular events in diabetic HFpEF patients.However,adjusted N-terminal pro-brain natriuretic peptide was not an independent prognostic factor.The cut-offvalue of GLS to predict outcome was-14.09%from ROC curve analysis.The Kaplan-Meier curve showed that in patients with and without hypertension and obesity,patients with the GLS>-14.09%had lower event-free survival compared to patients with GLS≤-14.09%(all P<0.05),and the ability of GLS to predict adverse outcomes was not affected by hypertension and obesity.Conclusions:GLS obtained by CMR feature-tracking strain analysis is an independent predictor of adverse outcomes in diabetic HFpEF,and its ability to predict adverse outcomes is independent of hypertension and obesity.

Objective:To investigate the changes and significance of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and procalcitonin, C-reactive protein, and interleukin-6 levels in neonates with septicemia.Methods:This study used a retrospective analysis mehod. A total of 69 neonates with septicemia who received treatment at the Neonatal Ward, Children's Hospital, The First People's Hospital of Chu Zhou were included in the study group. A total of 43 neonates without septicemia were included in the control group. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6 (IL-6) levels were compared between the two groups. The changes in NLR, MLR, PCT, and CRP levels in neonates with septicemia were observed after treatment, compared with their pre-treatment levels. The receiver operating characteristic curve was used to analyze the value of laboratory indicators NLR, MLR, and PCT, CRP, and IL-6 levels in the diagnosis of septicemia in neonates.Results:The NLR, MLR, and PCT, CRP, and IL-6 levels in the study group were (4.79 ± 1.87), (0.49 ± 0.21), (8.41 ± 3.21) μg/L, (11.97 ± 4.23) mg/L, and (892.13 ± 361.43) ng/L, respectively. These values were significantly higher than those in the control group [(0.89 ± 0.23), (0.13 ± 0.06), (0.51 ± 0.26) μg/L, (2.16 ± 1.26) mg/L, (111.28 ± 51.69) ng/L, t = 10.11, 9.76, 23.06, 36.72, 15.74, all P < 0.05]. After treatment, NLR, MLR, and PCT and CRP levels in the study group were (3.04 ± 1.42), (0.29 ± 0.13), (1.26 ± 0.52) μg/L, and (3.28 ± 1.87) mg/L, respectively. These values were significantly lower than those measured before treatment in the same group [(4.79 ± 2.47), (0.49 ± 0.19), (8.41 ± 3.41) μg/L, (11.97 ± 5.26) mg/L, t = 6.50, 6.33, 33.05, 39.04, all P < 0.05]. The areas under the curve for NLR, MLR, and PCT, CRP, and IL-6 levels in diagnosing septicemia in neonates were 0.785, 0.765, 0.665, 0.763, and 0.753, respectively, with NLR showing the highest area under the curve. Conclusions:NLR and MLR are valuable for diagnosing and evaluating the prognosis of neonatal septicemia. Combined detection of PCT, CRP, and IL-6 levels can enhance the sensitivity and specificity of septicemia diagnosis.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease. It has been reported in the literature that COPD patients with chronic airway mucus hypersecretion have more frequent acute exacerbations, more severe lung function decline, and higher hospitalizations and mortality. Therefore, it is particularly critical to understand the pathogenesis of hypersecretion of mucus in chronic obstructive pulmonary disease and find out effective treatment. This article focuses on the structure, significance of airway mucus and the mechanism of hypersecretion of mucus in chronic obstructive pulmonary disease (COPD). In addition, we also summarized drug and non-drug therapy for chronic airway mucus hypersecretion in this article. Drug therapy includes traditional drug therapy, some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy, and non-drug therapy includes smoking cessation, physical therapy and bronchos-copy therapy. We hope that it will provide new ideas and directions for the treatment of mucus hypersecretion in COPD patients.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease.It has been reported in the literature that COPD patients with chronic airway mucus hyperse-cretion have more frequent acute exacerbations,more severe lung function decline,and higher hos-pitalizations and mortality.Therefore,it is particu-larly critical to understand the pathogenesis of hy-persecretion of mucus in chronic obstructive pul-monary disease and find out effective treatment.This article focuses on the structure,significance of airway mucus and the mechanism of hypersecre-tion of mucus in chronic obstructive pulmonary dis-ease(COPD).In addition,we also summarized drug and non-drug therapy for chronic airway mucus hy-persecretion in this article.Drug therapy includes traditional drug therapy,some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy,and non-drug therapy includes smoking cessation,physical therapy and bronchos-copy therapy.We hope that it will provide new ideas and directions for the treatment of mucus hy-persecretion in COPD patients.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease.It has been reported in the literature that COPD patients with chronic airway mucus hyperse-cretion have more frequent acute exacerbations,more severe lung function decline,and higher hos-pitalizations and mortality.Therefore,it is particu-larly critical to understand the pathogenesis of hy-persecretion of mucus in chronic obstructive pul-monary disease and find out effective treatment.This article focuses on the structure,significance of airway mucus and the mechanism of hypersecre-tion of mucus in chronic obstructive pulmonary dis-ease(COPD).In addition,we also summarized drug and non-drug therapy for chronic airway mucus hy-persecretion in this article.Drug therapy includes traditional drug therapy,some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy,and non-drug therapy includes smoking cessation,physical therapy and bronchos-copy therapy.We hope that it will provide new ideas and directions for the treatment of mucus hy-persecretion in COPD patients.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease.It has been reported in the literature that COPD patients with chronic airway mucus hyperse-cretion have more frequent acute exacerbations,more severe lung function decline,and higher hos-pitalizations and mortality.Therefore,it is particu-larly critical to understand the pathogenesis of hy-persecretion of mucus in chronic obstructive pul-monary disease and find out effective treatment.This article focuses on the structure,significance of airway mucus and the mechanism of hypersecre-tion of mucus in chronic obstructive pulmonary dis-ease(COPD).In addition,we also summarized drug and non-drug therapy for chronic airway mucus hy-persecretion in this article.Drug therapy includes traditional drug therapy,some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy,and non-drug therapy includes smoking cessation,physical therapy and bronchos-copy therapy.We hope that it will provide new ideas and directions for the treatment of mucus hy-persecretion in COPD patients.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease.It has been reported in the literature that COPD patients with chronic airway mucus hyperse-cretion have more frequent acute exacerbations,more severe lung function decline,and higher hos-pitalizations and mortality.Therefore,it is particu-larly critical to understand the pathogenesis of hy-persecretion of mucus in chronic obstructive pul-monary disease and find out effective treatment.This article focuses on the structure,significance of airway mucus and the mechanism of hypersecre-tion of mucus in chronic obstructive pulmonary dis-ease(COPD).In addition,we also summarized drug and non-drug therapy for chronic airway mucus hy-persecretion in this article.Drug therapy includes traditional drug therapy,some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy,and non-drug therapy includes smoking cessation,physical therapy and bronchos-copy therapy.We hope that it will provide new ideas and directions for the treatment of mucus hy-persecretion in COPD patients.

Airway mucus hypersecretion is one of the important pathophysiological and clinical manifestations of chronic obstructive pulmonary disease.It has been reported in the literature that COPD patients with chronic airway mucus hyperse-cretion have more frequent acute exacerbations,more severe lung function decline,and higher hos-pitalizations and mortality.Therefore,it is particu-larly critical to understand the pathogenesis of hy-persecretion of mucus in chronic obstructive pul-monary disease and find out effective treatment.This article focuses on the structure,significance of airway mucus and the mechanism of hypersecre-tion of mucus in chronic obstructive pulmonary dis-ease(COPD).In addition,we also summarized drug and non-drug therapy for chronic airway mucus hy-persecretion in this article.Drug therapy includes traditional drug therapy,some new targeted drug therapy for pathogenesis and traditional Chinese medicine therapy,and non-drug therapy includes smoking cessation,physical therapy and bronchos-copy therapy.We hope that it will provide new ideas and directions for the treatment of mucus hy-persecretion in COPD patients.